← SynDRA
RIDAFOROLIMUS
SynDRA canonical compound SYN0030042 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | MTOR |
|---|
| Mechanism of action | mTOR inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- MTOR inhibitor
- Serine/threonine-protein kinase mTOR inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- SYK
- AAK1
- NEK7
- PIM1
- PHKG2
- PGRMC1
- PEBP1
- PDXK
- PDGFRB
- PAK4
- PAK2
- PAICS
- OPA1
- NUAK2
- NTRK1
- NQO2
- NLK
- PIM2
- PIP4K2A
- PIP4K2C
- PRKACG
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PKMYT1
- PRKACA
- PRKAA1
- PLK4
- PKN3
- PKN2
- PKN1
- NEK9
- NEK3
- PRKCQ
- MAPK14
- MAPKAPK2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- deforolimus
- AP23573
- MK-8669
- jenzyl
- AP-23573
- MK8669
- Deforolimus
- AP23573, MK-8669, Ridaforolimus, Deforolimus
- MK 8669
- Taltorvic
- AP 23573
- 48Z35KB15K
- Ridaforolimus, >80%
- CHEBI:79700
- Ridaforolimus [USAN]
- RIDAFOROLIMUS [MI]
- RIDAFOROLIMUS [INN]
- RIDAFOROLIMUS [JAN]
- Deforolimus (MK-8669)
- Ridaforolimus [USAN:INN]
- Ridaforolimus (MK-8669)
- RIDAFOROLIMUS [MART.]
- UNII-48Z35KB15K
- RIDAFOROLIMUS [WHO-DD]
- GTPL7884
- SCHEMBL7719298
- CHEMBL2103839
- DTXSID001025942
- NSC757440
- Rapamycin, 42-(dimethylphosphinate)
- s1022
- ZINC169677038
- CCG-270602
- CS-0122
- DB06233
- NSC-757440
- NCGC00346481-02
- HY-50908
Look up RIDAFOROLIMUS in the interactive SynDRA portal →